INCY vs TAK
Incyte vs Takeda Pharmaceutical Company Limited — AI-powered side-by-side comparison
VS
TAK
Takeda Pharmaceutical Company Limited
67
Insufficient Data
| Metric | INCY | TAK |
|---|
| AI Score |
72
|
67
|
| Price |
$121.08
|
$17.49
|
| P/E Ratio |
14.89×
|
48.87×
|
| ROE |
24.9%
|
2.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
62.1%
|
| Debt / Equity |
0.01×
|
0.65×
|
| Dividend Yield |
0.0%
|
3.6%
|
| RSI (14) |
56.2
|
61.6
|
| Beta |
0.769
|
0.088
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus TAK.
INCY leads by 5 points.
INCY scores 72/100 (Buy) versus TAK at 67/100 (Insufficient Data).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
TAK Committee View
67% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Price structure (LH_LL) contradicts the uptrend -- mixed signals — Technical